Evidence map›Paper›PMID 27863403›Full record

ArticleOncotarget2016

Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.

Evelyn Kidess-Sigal, Haiyan E Liu, Melanie M Triboulet, James Che, Vishnu C Ramani, Brendan C Visser, George A Poultsides, Teri A Longacre, Andre Marziali, Valentina Vysotskaia and 9 more

Open access · diamondAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 2 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Combinatorial Power of cfDNA, CTCs and EVs in Oncology.Diagnostics (Basel, Switzerland) · 2022
    Review
  19. Application of Microfluidics in Detection of Circulating Tumor Cells.Frontiers in bioengineering and biotechnology · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 3 countries.

Evelyn Kidess-SigalDepartment of Medicine, Division of Hepatology and Gastroenterology, Charité University Hospital, Berlin, Germany.
Haiyan E LiuVortex BioSciences, Inc., Menlo Park, CA, USA.
Melanie M TribouletDepartment of Surgery, Stanford University School of Medicine, Stanford, CA, USA.
James CheVortex BioSciences, Inc., Menlo Park, CA, USA.
Vishnu C RamaniDepartment of Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Brendan C VisserDepartment of Surgery, Stanford University School of Medicine, Stanford, CA, USA.
George A PoultsidesDepartment of Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Teri A LongacreDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Andre MarzialiBoreal Genomics, Vancouver, BC, Canada.
Valentina VysotskaiaCounsyl Inc., San Francisco, CA, USA.
Matthew WigginBoreal Genomics, Vancouver, BC, Canada.
Kyra HeirichDepartment of Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Violet HanftDepartment of Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Ulrich KeilholzComprehensive Cancer Center Charité, Berlin, Germany.
Ingeborg TinhoferDepartment of Radiooncology and Radiotherapy, Charité University Hospital, Berlin, Germany.
Jeffrey A NortonDepartment of Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Mark LeeGRAIL, Redwood City, CA, USA.
Elodie Sollier-ChristenVortex BioSciences, Inc., Menlo Park, CA, USA.
Stefanie S JeffreyDepartment of Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Stanford University · USCharité - Universitätsmedizin Berlin · DECollège Boréal · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment of advanced colorectal cancer (CRC) requires multimodal therapeutic approaches and need for monitoring tumor plasticity. Liquid biopsy biomarkers, including CTCs and ctDNA, hold promise for evaluating treatment response in real-time and guiding therapeutic modifications. From 15 patients with advanced CRC undergoing liver metastasectomy with curative intent, we collected 41 blood samples at different time points before and after surgery for CTC isolation and quantification using label-free Vortex technology. For mutational profiling, KRAS, BRAF, and PIK3CA hotspot mutations were analyzed in CTCs and ctDNA from 23 samples, nine matched liver metastases and three primary tumor samples. Mutational patterns were compared. 80% of patient blood samples were positive for CTCs, using a healthy baseline value as threshold (0.4 CTCs/mL), and 81.4% of captured cells were EpCAM+ CTCs. At least one mutation was detected in 78% of our blood samples. Among 23 matched CTC and ctDNA samples, we found a concordance of 78.2% for KRAS, 73.9% for BRAF and 91.3% for PIK3CA mutations. In several cases, CTCs exhibited a mutation that was not detected in ctDNA, and vice versa. Complementary assessment of both CTCs and ctDNA appears advantageous to assess dynamic tumor profiles.

Indexed as

MutationBiomarkers, TumorCirculating Tumor DNAClass I Phosphatidylinositol 3-KinasesColorectal NeoplasmsDNA Mutational AnalysisGenetic Predisposition to DiseaseHCT116 CellsHumansLab-On-A-Chip DevicesMicrofluidic Analytical TechniquesNeoplastic Cells, CirculatingPhenotypePredictive Value of TestsPrognosisProto-Oncogene Proteins B-rafBiomarkers, TumorBRAF protein, humanCirculating Tumor DNAClass I Phosphatidylinositol 3-KinasesKRAS protein, humanPIK3CA protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)circulating tumor cellscirculating tumor DNAcolorectal cancerliquid biopsyVortex

Identifiers

PMID27863403
PMCPMC5356741
OpenAlexW2550824805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.